RDPAC Medical Representatives Compliance (MRC) Test

RDPAC is a member and an active player of the global pharmaceutical industry association network, and one of the first industry organizations in China to attach such importance to compliance in the pharmaceutical industry. In order to further enhance the standardization and professionalization of drug promotion activities within the relevant workforce, RDPAC administers the Medical Representatives Compliance (MRC) Test (hereinafter referred to as the "MRC Test") to its member companies. This enhanced MRC Test was officially introduced on January 1, 2024.
RDPAC is set to extend the opportunity for the MRC Test registration to non-RDPAC member companies in June 2024, implementing the same test rules as those for RDPAC member companies (for details regarding test registration and other pertinent matters for non-RDPAC member companies, including score inquiries, please visit: http://mrc.rdpac.org).
The objective of the MRC Test is to deepen candidates’ comprehension of the safe and rational use of drugs, particularly among medical representatives, thus further propelling the standardization and professionalization of their drug promotion activities within the relevant workforce. By studying the necessary fundamentals in preparation for the MRC Test, candidates can reinforce and update their grasp of key knowledge areas encompassed in the industry's self-discipline rules, Chinese laws and regulations. By emphasizing compliance, the MRC Test is expected to unite industry professionals to promote compliance in the pharmaceutical industry while addressing the collective needs of participating companies and underscoring the importance of compliance.